Comment on: Lazo et al. NH2-Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes. Diabetes 2013;62:3189–3193
- 1Institute of Metabolic and Cardiovascular Diseases, Paul Sabatier University, Toulouse, France
- 2Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
- 3Department of Endocrinology, Diabetes and Nutrition, Charité University School of Medicine, Berlin, Germany
- Corresponding author: Andreas L. Birkenfeld, .
Lazo et al. (1) reported that plasma NH2-terminal pro–brain natriuretic peptide (NT-proBNP) levels, a cleavage product of brain natriuretic peptide (BNP), are inversely associated with diabetes risk in ∼7,800 healthy patients over a period of 12 years. In line with this, genetic evidence suggests a protective effect of BNP on diabetes risk (2). So far, mechanistic insight is lacking on how natriuretic peptides (NPs) …